As the Canakinumab Anti‐inflammatory Thrombosis Outcome Study [29] of 10 061 similarly overweight subjects with hsCRP > 2 mg/L has shown that treament with the IL‐1β neutralizing antibody canakinumab reduces CVD, we measured plasma IL‐1β concentrations in the overweight cohort. This evidence concerns the gene IL1B and deep vein thrombosis.